439. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.
作者: David Roth.;David R Nelson.;Annette Bruchfeld.;AnnMarie Liapakis.;Marcelo Silva.;Howard Monsour.;Paul Martin.;Stanislas Pol.;Maria-Carlota Londoño.;Tarek Hassanein.;Philippe J Zamor.;Eli Zuckerman.;Shuyan Wan.;Beth Jackson.;Bach-Yen Nguyen.;Michael Robertson.;Eliav Barr.;Janice Wahl.;Wayne Greaves.
来源: Lancet. 2015年386卷10003期1537-45页
Chronic hepatitis C virus (HCV) infection in patients with stage 4-5 chronic kidney disease increases the risk of death and renal graft failure, yet patients with hepatitis C and chronic kidney disease have few treatment options. This study assesses an all-oral, ribavirin-free regimen in patients with HCV genotype 1 infection and stage 4-5 chronic kidney disease.
|